INDICATIONS

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request
a Rep

SUPPORT AND RESOURCES: HCP AND PATIENT RESOURCES

REBLOZYL resources

Using sEPO ≤200 as a parameter in the LR-MDS treatment algorithm

George Yaghmour, MD

USC Norris Comprehensive Cancer Center & Hospital

Los Angeles, CA

Clinical response and duration in the RS- subgroups

Jamie Koprivnikar, MD

John Theurer Cancer Center Hackensack University Medical Center

Hackensack, NJ

Book icon Book icon

REBLOZYL First-line Clinical Data

View this summary of data regarding REBLOZYL as a first-line treatment for MDS-associated anemia.

Download Leave-Behind
Book icon Book icon

ESA Limitations Flashcard

Explore data highlighting unmet need for 1L MDS patients due to the limitations of ESAs and how REBLOZYL can help as a first-line treatment for patients with MDS-associated anemia.

Download Flashcard
Syringe icon Syringe icon

MDS First-line Dosing Guide

Clear and detailed guidance on dosing REBLOZYL to optimize response in first-line patients with MDS-associated anemia.

Download Guide
Syringe icon Syringe icon

MDS First-line Dosing and Reconstitution Guide

How to dose and administer REBLOZYL for your first-line patients with MDS-associated anemia.

Download Guide
Syringe icon Syringe icon

Beta-thalassemia Dosing Flashcard

Clear and detailed guidance on dosing REBLOZYL to optimize response in patients with beta-thalassemia.

Download Flashcard

Book icon Book icon

REBLOZYL MDS Patient Brochure

A guide for patients living with MDS-RS–associated anemia to learn more about REBLOZYL.

Book icon Book icon

MDS Education Brochure

Give this brochure to your patients and caregivers so they can learn more about MDS, MDS-associated anemia, and support for people living with MDS.

Download Brochure
Website icon Website icon

MDS Patient Website

An information-filled resource where MDS patients can sign up for information about REBLOZYL.

Visit Patient Site
Checklist icon Checklist icon

REBLOZYL Treatment Tracker

A tool to help you track your transfusions and communicate your symptoms to your healthcare team.

Download Tracker
Book icon Book icon

REBLOZYL Beta-thalassemia Patient Brochure

A guide for patients living with beta-thalassemia–associated anemia to learn more about REBLOZYL.

Download Brochure
Website icon Website icon

Beta-thalassemia Patient Website

An information-filled resource where beta-thalassemia patients with beta-thalassemia can sign up for information about REBLOZYL.

Visit Patient Site

These EMR system resources can be used to identify patients along the REBLOZYL treatment journey. They provide instructions for creating lists or alerts to identify MDS patients who might be good candidates for REBLOZYL or patients who are currently on REBLOZYL who may require a dose adjustment. Instructions below are for the following EMR systems: Epic, Cerner, OncEMR, iKnowMed, Agnostic, and AllScripts.

Epic

Patient Identification Resources

Instructions for creating a list of patients who may be a good fit for REBLOZYL.

Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.

Dosing Resources

Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.

Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.

Order Set Instructions

Instructions for creating an order set for REBLOZYL.

Cerner

Patient Identification Resources

Instructions for creating a list of patients who may be a good fit for REBLOZYL.

Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.

Dosing Resources

Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.

Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.

Order Set Instructions

Instructions for creating an order set for REBLOZYL.

OncEMR

Patient Identification Resources

Instructions for creating a list of patients who may be a good fit for REBLOZYL.

Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.

Dosing Resources

Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.

Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.

Order Set Instructions

Instructions for creating an order set for REBLOZYL.

iKnowMed

Patient Identification Resources

Instructions for creating a list of patients who may be a good fit for REBLOZYL.

Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.

Dosing Resources

Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.

Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.

Agnostic

Patient Identification Resources

Instructions for creating a list of patients who may be a good fit for REBLOZYL.

Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.

Dosing Resources

Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.

Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.

Order Set Instructions

Instructions for creating an order set for REBLOZYL.

AllScripts

Order Set Instructions

Instructions for creating an order set for REBLOZYL.

ESA=erythropoiesis-stimulating agent; LR-MDS=lower-risk myelodysplastic syndromes; MDS=myelodysplastic syndromes; RS=ring sideroblast; sEPO=serum erythropoietin.

SUPPORT AND RESOURCES: HCP AND PATIENT RESOURCES

REBLOZYL resources

Using sEPO ≤200 as a parameter in the LR-MDS treatment algorithm

George Yaghmour, MD

USC Norris Comprehensive Cancer Center & Hospital

Los Angeles, CA

Clinical response and duration in the RS- subgroups

Jamie Koprivnikar, MD

John Theurer Cancer Center Hackensack University Medical Center

Hackensack, NJ

Book icon Book icon

REBLOZYL First-line Clinical Data

View this summary of data regarding REBLOZYL as a first-line treatment for MDS-associated anemia.

Download Leave-Behind
Book icon Book icon

ESA Limitations Flashcard

Explore data highlighting unmet need for 1L MDS patients due to the limitations of ESAs and how REBLOZYL can help as a first-line treatment for patients with MDS-associated anemia.

Download Flashcard
Syringe icon Syringe icon

MDS First-line Dosing Guide

Clear and detailed guidance on dosing REBLOZYL to optimize response in first-line patients with MDS-associated anemia.

Download Guide
Syringe icon Syringe icon

MDS First-line Dosing and Reconstitution Guide

How to dose and administer REBLOZYL for your first-line patients with MDS-associated anemia.

Download Guide
Syringe icon Syringe icon

Beta-thalassemia Dosing Flashcard

Clear and detailed guidance on dosing REBLOZYL to optimize response in patients with beta-thalassemia.

Download Flashcard

Book icon Book icon

REBLOZYL MDS Patient Brochure

A guide for patients living with MDS-RS–associated anemia to learn more about REBLOZYL.

Book icon Book icon

MDS Education Brochure

Give this brochure to your patients and caregivers so they can learn more about MDS, MDS-associated anemia, and support for people living with MDS.

Download Brochure
Website icon Website icon

MDS Patient Website

An information-filled resource where MDS patients can sign up for information about REBLOZYL.

Visit Patient Site
Checklist icon Checklist icon

REBLOZYL Treatment Tracker

A tool to help you track your transfusions and communicate your symptoms to your healthcare team.

Download Tracker
Book icon Book icon

REBLOZYL Beta-thalassemia Patient Brochure

A guide for patients living with beta-thalassemia–associated anemia to learn more about REBLOZYL.

Download Brochure
Website icon Website icon

Beta-thalassemia Patient Website

An information-filled resource where beta-thalassemia patients with beta-thalassemia can sign up for information about REBLOZYL.

Visit Patient Site

These EMR system resources can be used to identify patients along the REBLOZYL treatment journey. They provide instructions for creating lists or alerts to identify MDS patients who might be good candidates for REBLOZYL or patients who are currently on REBLOZYL who may require a dose adjustment. Instructions below are for the following EMR systems: Epic, Cerner, OncEMR, iKnowMed, Agnostic, and AllScripts.

Epic

Patient Identification Resources

Instructions for creating a list of patients who may be a good fit for REBLOZYL.

Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.

Dosing Resources

Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.

Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.

Order Set Instructions

Instructions for creating an order set for REBLOZYL.

Cerner

Patient Identification Resources

Instructions for creating a list of patients who may be a good fit for REBLOZYL.

Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.

Dosing Resources

Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.

Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.

Order Set Instructions

Instructions for creating an order set for REBLOZYL.

OncEMR

Patient Identification Resources

Instructions for creating a list of patients who may be a good fit for REBLOZYL.

Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.

Dosing Resources

Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.

Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.

Order Set Instructions

Instructions for creating an order set for REBLOZYL.

iKnowMed

Patient Identification Resources

Instructions for creating a list of patients who may be a good fit for REBLOZYL.

Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.

Dosing Resources

Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.

Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.

Agnostic

Patient Identification Resources

Instructions for creating a list of patients who may be a good fit for REBLOZYL.

Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.

Dosing Resources

Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.

Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.

Order Set Instructions

Instructions for creating an order set for REBLOZYL.

AllScripts

Order Set Instructions

Instructions for creating an order set for REBLOZYL.

ESA=erythropoiesis-stimulating agent; LR-MDS=lower-risk myelodysplastic syndromes; MDS=myelodysplastic syndromes; RS=ring sideroblast; sEPO=serum erythropoietin.